FDA Panel Rejects Cystic Fibrosis Drug

(MedPage Today) — SILVER SPRING, Md. — An FDA advisory committee has voted against approval of liprotamase (Sollpura), a pancreatic enzyme product for cystic fibrosis and other diseases that cause pancreatic insufficiency, saying there is not enough evidence that the drug works better than agents already on the market.

Post a Comment

Comments are closed.